Loading...
Market
Where will the majority of First To Know Syphilis Test sales occur by end of 2024?
2
Resolution / Starting Odds
Mostly in the US • 25%
Mostly in Europe • 25%
Mostly in Asia • 25%
Evenly distributed globally • 25%
Sales reports and market analysis
Story
FDA Approves NOWDiagnostics' First At-Home Syphilis Test
Aug 16, 2024, 04:04 PM
The U.S. Food and Drug Administration (FDA) has granted De Novo Marketing Authorization to NOWDiagnostics for the First To Know Syphilis Test, marking the first at-home, over-the-counter test to detect Treponema pallidum (syphilis) antibodies in human blood. The test, developed by NOWDiagnostics, delivers results in about 15 minutes and aims to increase screening rates for syphilis, a sexually transmitted disease. Despite its convenience, the FDA cautioned that the test alone is not sufficient for a complete diagnosis, and further medical consultation is recommended.
View original story
Similar markets
Online Retailers • 25%
Pharmacy Chains • 25%
Healthcare Providers • 25%
Other • 25%
Families with children • 25%
Elderly individuals • 25%
Young professionals • 25%
Healthcare workers • 25%
Less than 3 stars • 25%
3 to 3.9 stars • 25%
4 to 4.4 stars • 25%
4.5 stars or more • 25%
New test leads market • 25%
Existing tests maintain dominance • 25%
Market share evenly distributed • 25%
Other outcome • 25%
Manufacturer A • 25%
Manufacturer B • 25%
Manufacturer C • 25%
Other • 25%
Manufacturer A has largest share • 25%
Manufacturer B has largest share • 25%
Manufacturer C has largest share • 25%
Manufacturer D or others have largest share • 25%
Walmart • 25%
CVS • 25%
Walgreens • 25%
Amazon • 25%
CVS • 25%
Walgreens • 25%
Rite Aid • 25%
Walmart Pharmacy • 25%
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,001 to 30,000 • 25%
More than 30,000 • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
